Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH). Methods: A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/ mL) groups at baseline. Follow-up for PSA was performed at the sixth postoperative month. Baseline and postoperative clinical parameters, functional parameters, PCa incidence, and postoperative changes in PSA were compared between the lowand high-PSA groups. Results: The baseline PSA of 1,296 patients (mean age, 69.7±6.8 years) was 4.0±4.1 ng/mL, with 712 patients (55.0%) in the low-PSA group (1.6±0.8 ng/mL), and 584 patients (45.0%) in the high-PSA group (6.9±4.7 ng/mL). Incidental PCa was detected in 82 patients (6.3%), with a similar incidence in the low-PSA (41 patients, 5.9%) and high-PSA (41 patients, 7.0%) groups (P>0.05). At 6 months postoperatively, both groups showed significant improvements in the maximum flow rate, postvoid residual volume, and all domains of the International Prostate Symptom Score (P<0.05). At postoperative 6 months, the PSA level significantly decreased by 66.6%±23.6% in all patients (54.3%±23.9% in the low-PSA group; 79.6%±14.7% in the high-PSA group) (P<0.05), and the PSA levels of 1,264 patients (97.6%) had normalized. Conclusions: In patients with elevated PSA presenting with LUTS/BPH, our study demonstrated significant improvements in functional parameters and decreased PSA after HoLEP. The incidental PCa detection rate did not show a statistically significant difference between the low- and high-PSA groups. Timely surgery for LUTS/BPH without delay due to PSA monitoring should be considered.
Abstract
Purpose: This study investigated functional outcomes in lower urinary tract symptoms (LUTS), the incidence of incidental prostate cancer (PCa), and changes in prostate-specific antigen (PSA) levels after holmium laser enucleation of the prostate (HoLEP) in patients with elevated PSA and benign prostatic hyperplasia (BPH). Methods: A retrospective review of a prospectively designed protocol for patients who underwent HoLEP at our institution from January 2010 to May 2020 was conducted. Patients were classified into low-PSA (<3.0 ng/mL) and high-PSA (≥3.0 ng/ mL) groups at baseline. Follow-up for PSA was performed at the sixth postoperative month. Baseline and postoperative clinical parameters, functional parameters, PCa incidence, and postoperative changes in PSA were compared between the lowand high-PSA groups. Results: The baseline PSA of 1,296 patients (mean age, 69.7±6.8 years) was 4.0±4.1 ng/mL, with 712 patients (55.0%) in the low-PSA group (1.6±0.8 ng/mL), and 584 patients (45.0%) in the high-PSA group (6.9±4.7 ng/mL). Incidental PCa was detected in 82 patients (6.3%), with a similar incidence in the low-PSA (41 patients, 5.9%) and high-PSA (41 patients, 7.0%) groups (P>0.05). At 6 months postoperatively, both groups showed significant improvements in the maximum flow rate, postvoid residual volume, and all domains of the International Prostate Symptom Score (P<0.05). At postoperative 6 months, the PSA level significantly decreased by 66.6%±23.6% in all patients (54.3%±23.9% in the low-PSA group; 79.6%±14.7% in the high-PSA group) (P<0.05), and the PSA levels of 1,264 patients (97.6%) had normalized. Conclusions: In patients with elevated PSA presenting with LUTS/BPH, our study demonstrated significant improvements in functional parameters and decreased PSA after HoLEP. The incidental PCa detection rate did not show a statistically significant difference between the low- and high-PSA groups. Timely surgery for LUTS/BPH without delay due to PSA monitoring should be considered.
참고문헌 (35)
- Roehrborn CG, "The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia", Int J Impot Res, 20(Suppl 3), pp.S19~S26 (2008)
- Nath CK, "Prostate-specific antigen density : a measurement to differentiate benign hypertrophy of prostate from prostate carcinoma", J Lab Physicians, 12, pp.44~48 (2020)
- Puppo P, "Repeated negative prostate biopsies with persistently elevated or rising PSA : a modern urologic dilemma", Eur Urol, 52, pp.639~641 (2007)
- Katz DA, "Health perceptions in patients who undergo screening and workup for prostate cancer", Urology, 69, pp.215~220 (2007)
- van Renterghem K, "A new algorithm in patients with elevated and", or rising prostatespecific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies, 2010, pp.42, 29~38
- Cho HJ, "The role of transurethral resection of the prostate for patients with an elevated prostatespecific antigen", Prostate Int, 2, pp.196~202 (2014)
- Tinmouth WW, "Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate : a marker for completeness of adenoma resection", J Endourol, 19, pp.550~554 (2005)
- Elkhodair S, "The role of the IPSS(International Prostate Symptoms Score)in predicting acute retention of urine in patients undergoing major joint arthroplasty", Surgeon, 3, pp.63~65 (2005)
- Kang M, "Urodynamic features and significant predictors of bladder outlet obstruction in patients with lower urinary tract symptoms", benign prostatic hyperplasia and small prostate volume, 2016, pp.89, 96~102
- Hwang SI, "The future perspectives in transrectal prostate ultrasound guided biopsy", Prostate Int, 2, pp.153~160 (2014)
- L. Xu, "Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population", Andrologia, 50(2), pp.e12872~ (2017), Hindawi Limited[DOI]
- Kim SJ, "A randomized controlled comparison between periprostatic nerve block and pelvic plexus block at the base and apex of 14-core prostate biopsies", World J Urol, 37, pp.2663~2669 (2019)
- Yoo S, "A novel biopsyrelated parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy : a useful parameter for predicting tumor volume compared to number of positive cores", J Cancer Res Clin Oncol, 144, pp.135~143 (2018)
- 오승준, "Current surgical techniques of enucleation in holmium laser enucleation of the prostate", Investigative and Clinical Urology, 60(5), pp.333~342 (2019), 대한비뇨의학회[DOI]
- Sarıkaya S, "Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature", Arch Ital Urol Androl, 86, pp.288~290 (2014)
- Songzhe Piao, "Holmium Laser Enucleation of the Prostate is Safe for Patients Above 80 Years: A Prospective Study", International Neurourology Journal, 20(2), pp.143~150 (2016), 대한배뇨장애요실금학회
- Ilic D, "Prostate cancer screening with prostate-specific antigen(PSA)test : a systematic review and meta-analysis", BMJ, 362, pp.k3519~ (2018)
- Leal J, "Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-offlevels : a UK case study", Cancer Epidemiol, 52, pp.99~105 (2018)
- Rashid MM, "Efficacy of lower cut offvalue of serum prostate specific antigen in diagnosis of prostate cancer", Bangladesh Med Res Counc Bull, 38, pp.90~93 (2012)
- Woo HY, "Association of prostate specific antigen concentration with lifestyle characteristics in Korean men", Asian Pac J Cancer Prev, 13, pp.5695~5699 (2012)
- Romero-Otero J, "Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia : outcomes and complications of 10years of routine clinical practice", BJU Int, 126, pp.177~182 (2020)
- Helfand BT, "Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia", Urology, 74, pp.177~183 (2009)
- Ozden C, "Detection of prostate cancer and changes in prostate-specific antigen(PSA)six months after surgery for benign prostatic hyperplasia in patients with elevated PSA", Urol Int, 71, pp.150~153 (2003)
- Nunez R, "Incidental prostate cancer revisited : early outcomes after holmium laser enucleation of the prostate", Int J Urol, 18, pp.543~547 (2011)
- Ahyai SA, "Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate(HoLEP) : a prospective study", World J Urol, 38, pp.3207~3217 (2020)
- Lee YJ, "Patient satisfaction after holmium laser enucleation of the prostate(HoLEP) : a prospective cohort study", PLoS One, 12, pp.e0182230~ (2017)
- Cho MC, "Self-assessed goal achievement(SAGA)after Holmium laser enucleation of the prostate(HoLEP) : association with patients’ postoperative satisfaction", PLoS One, 13, pp.e0203825~ (2018)
- 박호균, "Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (＞3.0 ng", mL): Risks and Benefits Based on Biopsy Results and Follow-up Status, 2014, pp.55(4), 249~253[DOI]
- Elkoushy MA, "Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression", Urology, 86, pp.552~557 (2015)
- Rosenhammer B, "HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP : a matched-pair analysis", World J Urol, 36, pp.2035~2041 (2018)
- Zackrisson B, "Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening", Eur Urol, 43, pp.327~332 (2003)
- Capogrosso P, "Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia", Urology, 122, pp.152~157 (2018)
- Borer JG, "Age specific prostate specific antigen reference ranges : population specific", J Urol, 159, pp.444~448 (1998)
- Ryoo H, "Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsynaive and prior biopsy-negative patients", Prostate Int, 8, pp.125~129 (2020)
- Porreca A, "Preoperative multiparametric prostate magnetic resonance imaging : a safe clinical practice to reduce incidental prostate cancer in Holmium laser enucleation of the prostate", Cent European J Urol, 72, pp.106~112 (2019)